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Background: The purpose of this study was to identify differences in perceptions of care 
regarding postherpetic neuralgia, including communication patterns between patients and 
physicians and levels of satisfaction with therapies and care.
Methods: A survey was developed for physicians (neurologists, internists, and family 
  physicians) and patients with postherpetic neuralgia in order to determine their perspectives 
on its management.
Results: A total of 142 eligible patient respondents were included in the study, and responses 
were compared with those of 150 primary care physicians and 76 neurologist respondents. 
Few patients and physicians indicated satisfaction with the currently available treatments for 
postherpetic neuralgia. While nearly all physicians responded that they discuss the cause of 
postherpetic neuralgia with a patient, one in four patients indicated that their physician did not 
discuss the cause. Similarly, one in four patients were not aware of the duration of postherpetic 
neuralgia, the treatment side effects, or what to expect from treatment. Patients may be less likely 
to discuss treatment side effects and quality of life issues than physicians perceive.
Conclusion: Physicians and patients have similar perceptions regarding treatment options for 
postherpetic neuralgia; however, certain gaps in communication were evident, which may be 
attributable to physician knowledge and communication skills with patients. Strategies to improve 
issues of expected outcomes and side effects of treatment may be useful to physicians.
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Introduction
Herpes zoster, a generally localized, painful rash, is the reactivation of latent varicella 
zoster virus that has been dormant in the spinal ganglia or cranial sensory nerves 
since the primary infection.1 Approximately one in three individuals in the US will 
experience herpes zoster in their lifetime, and the risk increases with age.2 Annually, 
there are approximately one million new cases in the US.2 When pain associated with 
herpes zoster persists for more than 3 months beyond resolution of the rash, it is termed 
postherpetic neuralgia.3 Postherpetic neuralgia results from both inflammation and 
viral damage to peripheral and central axons in sensory neurons, dorsal horn atrophy, 
and peripheral and central sensitization.1,4 Postherpetic neuralgia occurs in 10%–18% 
of individuals with herpes zoster, and 48% are still symptomatic at one year.2,3 The 
pain of postherpetic neuralgia may vary from mild to severe and may be intermittent 
or constant.2 It adversely impacts quality of life, causing disruption to sleep, daily 
activities, and work.5Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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In 2004, the Quality Standards Subcommittee of the 
American Academy of Neurology published an evidence-
based practice parameter for the management of postherpetic 
neuralgia.3 Pharmacologic agents recommended by the 
American Academy of Neurology for the management 
of postherpetic neuralgia include gabapentin, pregabalin, 
tricyclic antidepressants, opioids, and topical lidocaine 
patches. Although this document provides guidance with 
respect to choice of agents, no recommendations are made 
for sequence or combination of use. Despite the number of 
options available, management remains complex, with no 
one medication addressing the multiple pain pathways active 
in postherpetic neuralgia. Most patients require use of more 
than one agent.1 While the use of two or more agents allows 
for greater pain relief at lower doses of each individual drug 
(and potentially fewer adverse effects), it also increases the 
risk of drug interactions and decreased patient adherence.1
Recent research has found that a substantial fraction 
of patients with postherpetic neuralgia are not treated as 
suggested in the American Academy of Neurology guidelines, 
receiving nonrecommended agents and/or subtherapeutic 
doses, and, for many, treatment is ineffective.6 A survey 
of internists and family practitioners found the median 
number of yearly patient visits for postherpetic neuralgia 
recalled by these physicians was four; most (.60%) of these 
patients were referred for specialty care, with 30% referred 
to neurologists.7
In order to determine the informational needs of 
physicians managing patients with postherpetic neuralgia, we 
designed the multifaceted BASIK (Barriers, Attitudes, Skills, 
Identified gaps, and Knowledge) postherpetic neuralgia 
study. Components of this study included examining both 
physician and patient perceptions on the management of 
postherpetic neuralgia. Here, we describe key gaps between 
these perceptions.
Materials and methods
survey development and distribution
In order to develop a survey that provides insight into 
the issues faced by physicians managing patients with 
postherpetic neuralgia, a literature review of previously 
published studies examining gaps in the management 
of patients with postherpetic neuralgia by US-based 
primary care physicians and neurologists was conducted. 
The studies were published between 2000 and 2009, and 
the literature review was conducted in November 2009. 
The BASIK postherpetic neuralgia survey was developed 
from this research. Case-vignette survey development began 
with the neurologist version of the survey. This survey 
was reviewed by two US-practicing neurologists in order 
to determine accuracy and relevance to the neurologist 
audience. Once the neurologist survey tool was complete, 
this survey was adapted to fit the scope of practice of primary 
care physicians and was again reviewed by two US-practicing 
primary care physicians before distribution.
In November 2009, email invitations to participate in 
the physician case-vignette surveys were sent to a nationally 
representative random sample of 450 US primary care 
physicians and 225 US neurologists, obtained from the 
American Medical Association Masterfile, 2008. Inclusion 
criteria for physician participation were that they must 
be currently practicing and see at least one patient with 
postherpetic neuralgia per week.
A patient survey was created in conjunction with the 
physician survey to assess patient pain intensity, level of 
agreement with statements regarding their postherpetic 
neuralgia management, types of medications prescribed, 
and satisfaction with prescribed medications and care. 
Question types included multiple-choice and 7-point Likert 
scale rating questions. The patient survey was submitted 
and approved by the Western Institutional Review Board 
(Olympia, WA) in October 2009. The patient survey was 
launched during December 2009 and January 2010 as 
an online-survey questionnaire and was made available 
to patients with postherpetic neuralgia who visited the 
shingles website at WebMD (http://www.webmd.com/
skin-problems-and-treatments/shingles/default.htm). 
Patients meeting the defined inclusion criteria were given 
the opportunity to complete the survey. The inclusion 
criteria were as follows: patients must have been 18 years 
of age or older, reside in the US, have been diagnosed 
with herpes zoster, have had pain that remained after the 
shingles rash went away (remaining pain lasting 6 months 
or longer), and were prescribed medication for the pain. 
The survey elements included in the portions of the study 
focused on in this paper can be found in Appendix A and 
Appendix B.
statistical analysis
Data were first summarized by frequencies (PASW 
Statistics 18; SPSS Inc, Chicago, IL). In order to compare 
physician and patient responses, rating scale questions 
were transformed into categorical variables containing 
three levels where the mid-point was defined as neutral. Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Pearson’s Chi-square analysis was used to compare the 
responses between physicians and patients. Significance was 
established at P , 0.05.
Results
Physician survey
The physician responses from the BASIK   postherpetic neural-
gia study were collected during November 2009. The response 
rate for the physician surveys was approximately 36%. Two 
hundred and thirty-five responses (78   neurologists and 157 
primary care physicians) were collected, and nine (two neu-
rology respondents and seven primary care   physician respon-
dents) were excluded because they did not see patients with 
postherpetic neuralgia. The final sample contained 76 neu-
rologists and 150 primary care   physicians (Table 1). The phy-
sician sample from the BASIK postherpetic neuralgia study 
sample showed that primary care physicians reported seeing, 
on average, 116 patients per week, with an estimated 4% of 
their patients having postherpetic neuralgia. Neurologists 
reported seeing, on average, 86 patients per week, with an 
estimated 4% of their patients having postherpetic neuralgia. 
This translates to about five and three patients per week seen 
with postherpetic neuralgia, respectively.
Patient survey
One hundred and forty-two patient responses were collected 
during December 2009 and January 2010 (Table 2). A response 
rate for the patient survey was unattainable due to the fact 
that participants were not emailed an invitation to participate; 
rather, they were invited to participate via a link on the shingles 
website at WebMD. The majority of patient respondents were 
white non-Hispanic (86%) females (71%) aged 50–59 years 
(36%) with 1–3 years of college or technical education and 
currently receiving treatment or medication for pain (67%). 
Patients reported a mean pain rating of 9.34 on a 10-point rating 
scale when the pain from their postherpetic neuralgia was at 
its worst and a current mean pain rating of 5.79.
Physician-patient communication about 
postherpetic neuralgia
Results comparing perceptions of patients and physicians 
are summarized in Table 3. While 83% of primary care 
physicians and 78% of neurologists said that they talked 
about the cause of pain after shingles with postherpetic 
neuralgia patients, 70% of patients said their doctor 
had this discussion with them. When asked if their 
physician had specifically told them that their diagnosis 
was “postherpetic neuralgia,” 55% of patients answered 
affirmatively. Sixty-four percent of primary care physicians 
Table 1 Demographics of physician sample
PCP 
n = 150
Neurologist 
n = 76
Gender, percent male 72% 79%
Years in practice, mean (sD) 23 (12) 23 (8)
specialty  
  Family practice 
  internal medicine
 
44% 
56%
 
– 
–
Practice location 
  Urban 
  suburban 
  Rural
 
32% 
50% 
18%
 
26% 
61% 
13%
Present employment 
  independent 
  Group 
  Other*
 
29% 
64% 
7%
 
41% 
50% 
9%
Patients seen per week, mean (sD) 116 (57) 86 (52)
Patients seen per week with  
Phn, mean (sD)
5 (13) 4 (4)
Note: *“Other employment” includes medical school, health maintenance organization, 
government, and nongovernment hospitals. 
Abbreviations: sD, standard deviation; Phn, postherpetic neuralgia; PcP, primary 
care physician.
Table 2 Demographics of patient sample
Patients 
n = 142
Gender, percent male 29%
Age  
  40–49 years 
  50–59 years 
  60–69 years 
  70–79 years
 
20% 
36% 
20% 
13%
currently receiving treatment or medication for pain 67%
Race/ethnicity 
  White, not of hispanic origin 
  Black or African American, not of hispanic origin 
  hispanic
 
86% 
9% 
2%
highest grade completed Grade 12 or GeD 
  college or technical school 1–3 years 
  college 4 or more years or college degree 
  Graduate school 1 or more years
20% 
47% 
13% 
16%
Patient’s pain rating at its worst*, mean (sD) 9.3 (1.7)
Patient’s pain rating time of survey, mean (sD) 5.8 (2.4)
Prescribing physician 
  Family physician 
  internist 
  neurologist 
  Pain specialist 
  Other**
 
62% 
16% 
7% 
5% 
9%
Notes: *Pain rated on 1–10 scale, with 10 indicating highest; **“other prescribers” 
includes emergency physician, dermatologist, or infectious disease specialist. 
Abbreviation: sD, standard deviation.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Table 3 summary of physician and patient perceptions on Phn care
PCP 
(n = 150)
Neurologist 
(n = 76)
Patient 
(n = 142)
P value*
Physician discussed cause of pain after shingles 
  Disagree 
  neutral 
  Agree
 
0.7% 
16.7% 
82.7%
 
0.0% 
22.4% 
77.6%
 
22.5% 
7.7% 
69.7%
,0.001
Physician specifically told the patient they had “PHN” 
  Disagree 
  neutral 
  Agree
 
1.3% 
34.2% 
64.4%
 
1.3% 
21.1% 
77.6%
 
28.2% 
16.9% 
54.9%
,0.001
Patients are aware of the duration of Phn 
  Disagree 
  neutral 
  Agree
 
1.3% 
33.3% 
65.3%
 
3.9% 
43.4% 
52.6%
 
21.1% 
5.6% 
73.2%
,0.001
Patients understand what to expect from treatment 
  Disagree 
  neutral 
  Agree
 
3.4% 
54.4% 
42.3%
 
0.0% 
53.9% 
46.1%
 
27.5% 
9.2% 
63.4%
,0.001
The treatment is able to control pain** 
  Disagree 
  neutral 
  Agree
 
2.0% 
82.3% 
15.6%
 
0.0% 
81.3% 
18.7%
 
32.4% 
36.6% 
31.0%
,0.001
Physicians discuss potential treatment side effects 
  Disagree 
  neutral 
  Agree
 
0.0% 
42.2% 
57.8%
 
1.3% 
32.0% 
66.7%
 
23.2% 
38.7% 
38.0%
,0.001
Patients are aware of potential treatment side effects 
  Disagree 
  neutral 
  Agree
 
1.4% 
45.9% 
52.7%
 
1.3% 
35.5% 
63.2%
 
9.9% 
23.2% 
66.9%
,0.001
Patients discuss treatment side effects with physicians 
  never or rarely 
  sometimes 
  Often or always
 
1.3% 
15.3% 
83.3%
 
0.0% 
7.9% 
92.1%
 
17.6% 
31.0% 
51.4%
,0.001
Patients discuss quality of life issues with physicians 
  no 
  Yes
 
25.2% 
74.8%
 
13.3% 
86.7%
 
58.5% 
41.5%
,0.001
satisfaction with current Phn treatments 
  Dissatisfied 
  neutral 
  Satisfied
 
2.7% 
91.3% 
6.0%
 
0.0% 
92.1% 
7.9%
 
15.5% 
62.0% 
22.5%
,0.001
Follow-up scheduled in 1–3 months 
  no 
  Yes
 
18.7% 
81.3%
 
9.2% 
90.8%
 
40.1% 
59.9%
,0.001
More patient information on Phn is needed 
  Disagree 
  neutral 
  Agree
 
20.0% 
60.7% 
19.3%
 
36.8% 
53.9% 
9.2%
 
22.5% 
43.7% 
33.8%
,0.001
Notes: *A Chi-square test was conducted on the combined physician versus patient responses for each option; **for this selection, physicians rated their confidence, and 
patients rated treatment effectiveness. 
Abbreviations: PcP, primary care physician; Phn, postherpetic neuralgia.
and 78% of neurologists indicated that they specifically 
told patients that they had “postherpetic neuralgia.” With 
respect to communicating how long postherpetic neuralgia 
would last, 65% of primary care physicians and 53% of 
neurologists agreed that they do discuss this, while 73% of 
patients agreed that their physicians had talked about this 
with them. Finally, 63% of patients felt they understood 
what to expect from treatment, while only 42% of primary 
care physicians and 46% of neurologists felt patients 
understood this.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Opinions on treatment efficacy and safety
Physicians were doubtful about the ability of treatment to 
control pain associated with postherpetic neuralgia, with 
only 16% of primary care physicians and 19% of neurologists 
ranking themselves as very confident that the chosen 
treatment would control a patient’s pain; however, 31% of 
patients said their medications were effective for pain control. 
With respect to physician discussion of potential treatment 
side effects, 58% of primary care physicians and 67% of 
neurologists claimed to discuss this with their patients; 
only 38% of patients recalled this being discussed. Patient 
awareness of side effects was similar, as 53% of primary care 
physicians and 63% of neurologists thought patients were 
aware of medication side effects; however, 67% of patients 
said that they were aware of potential side effects associated 
with their medication. Only 6% of primary care physicians 
and 8% of neurologists were satisfied with currently available 
postherpetic neuralgia treatments, but 23% of patients said 
they were satisfied.
Of interest, a majority of physicians perceived that 
their patients discuss their treatment side effects (83% 
of primary care physicians and 92% of neurologists) and 
quality of life issues (75% of primary care physicians and 
87% of neurologists), but the patients claimed that they 
may not always do so. Only 51% of patients said that they 
often or always discussed side effects with their physician 
and 42% discussed quality of life issues.
Follow-up and education
Although 81% of primary care physicians and 91% of 
neurologists said they scheduled a follow-up visit for patients 
in 1–3 months, only 60% of patients said they were re-
evaluated that quickly, and 25% said there was no follow-up 
visit scheduled. One-third of patients thought there was a 
need for more patient education on postherpetic neuralgia, but 
only 19% of primary care physicians and 9% of neurologists 
thought this was a need.
Discussion
Postherpetic neuralgia can be a debilitating condition that 
takes a toll on a patient’s quality of life. Available guide-
lines suggest effective agents based on current evidence 
but do not provide a specific algorithm for management, 
leaving choice of agents and timing of evaluation to physi-
cian discretion. Physician-patient communication about the 
efficacy of postherpetic neuralgia management is therefore 
a crucial part of optimizing care. Recent studies in other 
disease states have demonstrated that physicians and patients 
perceive their interactions differently, and this may lead to 
misunderstandings about diagnosis, the severity of a condi-
tion, and therapeutic risks and benefits.8,9 We sought to evalu-
ate the practice patterns of physicians caring for patients with 
postherpetic neuralgia, including the barriers to optimal care, 
and to   discover how these patients viewed their care.
A number of communication gaps came to light in our 
study. The percentage of physicians who said they talked 
about the cause of postherpetic neuralgia and specifically 
told patients that they had postherpetic neuralgia was higher 
than the percentage of patients who said those issues were 
discussed with them. These disparities could result from a 
number of situations. It may be that physicians think they 
are discussing these issues with patients and they are not, or 
that physicians are talking about the etiology of postherpetic 
neuralgia and its diagnosis in terms patients cannot 
understand. Interestingly, the percentage of patients who said 
they had been told how long postherpetic neuralgia would 
last and what to expect from treatment was higher than the 
percentage of physicians who said they discussed this. The 
lower percentage of physicians who thought they discussed 
these issues brings up the question of the importance 
placed by physicians on educating patients about these 
issues, although they in fact seem to be discussing this with 
patients.
A clear lapse in communication was seen around treatment 
efficacy and safety. Far fewer physicians were confident in 
their ability to treat postherpetic neuralgia and were satisfied 
with available therapies compared with the percentage of 
patients who felt their medication was effective and were 
happy with the current treatments. It may be that physicians 
have more memory of patients with difficult-  to-treat 
postherpetic neuralgia or who frequently complain about their 
medications and thus physician opinion is negatively skewed. 
Also, patient satisfaction could potentially be increased 
due to switching to more effective medications through the 
course of the illness. Physicians thought that they discussed 
potential treatment side effects more often than patients 
recalled holding these discussions. Interestingly, almost twice 
as many patients said they were aware of potential treatment 
side effects than said that physicians discussed this with them. 
Patients may not recall having a discussion on side effects 
with their physicians, or this may be related to our patient 
sample, which was computer-literate and may have searched 
for this information on their own.
Of concern is the disparity concerning how often 
patients discuss side effects and quality of life issues with 
their physicians. Based on these responses, physicians may Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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be unaware of the times when patients may be holding 
information back from their physicians, potentially leading 
to gaps in proper care and treatment satisfaction.
A significant disparity also exists between physician 
and patient perceptions of follow-up care. A large majority 
of physicians thought they scheduled follow-up care within 
1–3 months, but only two-thirds of patients said they were 
re-evaluated in that time frame, and one quarter of patients 
said they had no follow-up at all. Physician self-assessment 
of follow-up care of postherpetic neuralgia patients may lead 
to improved outcomes if patients are seen more frequently.
Finally, it is clear that patients want more education, and 
physicians are less likely to perceive this need. This result 
particularly highlights the gap between physician conception 
of interaction with patients and the reality of the situation.
One of the main limitations to this study is that the 
  surveyed patients were not nested to the physician sample, 
so we cannot directly measure if the physicians’ perceptions 
hold true to the patients they actually manage. Future studies 
on these gaps in communication would be needed to link 
such perceptions of care directly. Additionally, because 
the patient-survey link was posted on a medical education 
website, the presumption might be that patients responding to 
the survey were computer-literate and may have been actively 
seeking information about their condition. Therefore, they 
may have not been representative of the general population 
of patients with postherpetic neuralgia. If patients were on 
the website seeking information about their condition, there 
may have been bias in that these patients were not completely 
satisfied with the care offered by their managing physician. 
Another possibility is that information obtained from the 
referring website may have been misremembered and 
misattributed to an interaction with a physician. Physicians 
and patients received nominal compensation for their 
completion of the survey, which could have created a small 
participation bias.
These gaps in physician-patient communication and 
perception are clear barriers to optimizing care of patients 
with postherpetic neuralgia. The development of office 
protocols may help alleviate some of these problems, which 
could potentially result from a lack of follow-up care due 
to miscommunication. Physician education in small group 
sessions may be useful to facilitate discussions and practice 
communication techniques. These techniques may include 
using simpler, less scientific language, speaking more slowly 
to give patients time to digest information, speaking more 
loudly for patients with hearing difficulties, and providing 
take-home information in a legible format written at a patient 
level. Physicians may find that short videos are helpful for 
some patients. In addition, physicians can help patients 
become better communicators by encouraging them to write 
down what they would like to discuss prior to the visit and by 
bringing a companion who can also listen to instructions.
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Appendix A 
Physician survey items
case
Michael is a 68-year-old African-American male who presents to your office with pain in the left face. He had acute herpes 
zoster 9 months ago with the rash located in the V1 distribution and the course was complicated by corneal involvement. 
Antiviral therapy and acetaminophen with codeine were initiated about a week after the onset of the rash. The rash resolved 
approximately 4 months ago, but he was left with a constant severe pain, which was rated 7/10 and described as burning 
with intermittent sharp, shooting pains in his left forehead and eye. He is not sleeping well because his pain frequently 
awakens him. On examination, there is scarring of the skin over the left forehead with loss of sensation to light touch and 
temperature in the area of scarring. You diagnose him with postherpetic neuralgia.
1.  How soon would you plan to see this patient after starting therapy? (select only one)
 Generally, no follow-up is scheduled
 Every 1–3 months until symptoms resolve
 Every 4–6 months until symptoms resolve
 Other (please specify): _______________________
2.  How confident are you that your initial treatment choice will control this patient’s pain?
1 2 3 4 5 6 7
not at all confident  somewhat confident  extremely confident
3.  Overall, how satisfied are you with currently available treatments for PHN? (select only one)
      
  Extremely 
dissatisfied
  Very  
dissatisfied
Dissatisfied   Somewhat 
satisfied
Satisfied   Very  
satisfied
  Extremely  
satisfied
4.  Please rate your level of agreement with each of the following statements. (select only one for each)
Strongly          Neutral  Strongly 
disagree  agree
I usually explain the cause of the pain to my patients before  
I begin treating it.
1 2 3 4 5 6 7
My patients are aware that PHN may last indefinitely. 1 2 3 4 5 6 7
Based on my explanation, my patients understand when they will  
begin to see pain relief from the medications I prescribe.
1 2 3 4 5 6 7
My patients are aware of the potential side effects associated with  
the medications I prescribe for their PHN.
1 2 3 4 5 6 7
My patients are likely to discuss with me the side effects they  
experience with their PHN medications.
1 2 3 4 5 6 7
When I diagnose patients with PHN, I typically tell them they  
have “post herpetic neuralgia.”
1 2 3 4 5 6 7
My patients need more information about PHN. 1 2 3 4 5 6 7Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
414
Glauser et al
5.  How often do your patients discuss the side effects of their PHN medication with you? (select only one)
  Never
(0% of the time)
  Rarely
(,25% of the time)
  Sometime
(25%–50% of the time)
  Often
(51%–75% of the time)
  Nearly always
(76%–100% of the time)
6.  How often do your patients discuss how PHN and its treatments affect their quality of life? (select only one)
   Never
(0% of the time)
 Rarely
(,25% of the time)
 Sometime
(25%–50% of the time)
 Often
(51%–75% of the time)
   Nearly always
(76%–100% of the time)
7.  Approximately how many patients do you see each week? __________________/per week
8.  Approximately what percentage of your patients has PHN? _________________%
Abbreviation: PHN, postherpetic neuralgia
Appendix B
Patient survey items
1.  Please rate your level of pain after shingles at its worst (choose one number)
No pain                                                                     Pain as bad as 
                                                                          you can imagine
0 1 2 3 4 5 6 7 8 9 10
2.  Please rate your level of pain now (choose one number)
No pain                                                                     Pain as bad as 
                                                                          you can imagine
0 1 2 3 4 5 6 7 8 9 10
3.  What type of physician prescribed medication(s) for your pain that occurred after the shingles rash? (select only one)
 Family medicine
 Internist
 Neurologist
 Pain specialist
 Other (please specify): ______________________
4.  At the time your physician gave you a prescription for the pain, did your physician discuss any of these topics with you? 
(select only one for each)
The cause of the pain after your shingles  Yes  No  Don’t remember
What to expect from medication used to manage the pain after shingles  Yes  No  Don’t remember
That pain after shingles may remain for a long time  Yes  No  Don’t remember
5.  Did your physician tell you specifically that you had “post-herpetic neuralgia”?
 Yes   No   Don’t rememberJournal of Pain Research
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communication gaps concerning postherpetic neuralgia
6.  How soon after you started taking your medication(s) for the pain after the shingles did your physician ask you to schedule 
a follow-up appointment? (select only one)
 No follow-up was scheduled
 Within the 1–3 months after starting my medication
 Within the first 4–6 months after starting my medication
 Other (please specify): ___________________________
7.  Have you ever discussed how your treatment of pain after shingles affects your quality of life with your doctor?
 Yes
 No
8.  Overall, how effective at relieving your pain was the medication(s) your doctor prescribed initially for your pain after 
shingles? (select only one)
     
Not at all effective Not very effective   Somewhat 
effective
  Somewhat effective Very effective   Extremely  
effective
9.  Overall, how satisfied were you with the medication(s) you received for the pain after shingles? (select only one)
      
  Extremely 
dissatisfied
  Very  
dissatisfied
Dissatisfied   Somewhat 
satisfied
Satisfied   Very  
satisfied
  Extremely  
satisfied
10. Please rate your level of agreement with these statements about your pain after shingles (select only one for each)
Strongly  Neutral  Strongly 
disagree  agree
I clearly understand the side effects I should watch for when I take  
my pain medication.
1 2 3 4 5 6 7
If I experience side effects from my medication, I always let my  
physician know.
1 2 3 4 5 6 7
11. Please rate your level of agreement with these statements about your pain after shingles (select only one for each)
Strongly  Neutral  Strongly 
disagree  agree
I needed more information to manage my pain. 1 2 3 4 5 6 7
My doctor clearly explained the possible side effects of my pain  
medications.
1 2 3 4 5 6 7